2. Atrial Fibrillation
AF is a supraventricular tachyarrhythmia
characterized by uncoordinatedatrial activation with
consequent deterioration of atrial
mechanical function.
3. A rapid, irregular, sustained, wide-QRS-
complextachycardia strongly suggests AF with
conduction over an accessorypathway or AF with
underlying bundle-branch block. Extremelyrapid rates
(over 200 beats per minute) suggest the presenceof an
accessory pathway or ventricular tachycardia.
4. Prevalence:
In US <1% ‘ve AF;
Varies with age –
Rare in children & young adults.
Is also rare < 60 yrs.
> 8% in > 80 yrs.
Median age 75 yrs.
5.
6. Presence of very irregular & disorganized atrial activity
represented - as Fibrillatory waves; aka “F” waves,
These are due to several independent reentrant wavelets
within atria
7. F waves - fine or coarse ; varying morphologies
F waves may not be present; flat line with irreg irreg R-R
seen.
A. rate - ≥350 bts/min.
V. rate- irreg irreg & depends on # of atrial impulses
conducted through AVN.
QRS complexes are narrow unless - BBB, aberrant
conduction, or preexcitation
8. Coarse f waves –
RHD MV ds,
Thyrotoxicosis,
Emphysema,
Hypertensive CVD
Fine f waves – Arteriosclerotic hrt dis.
9.
10.
11. 6 Sec time lines:
6 sec = 30 large blocks.
# QRS in 6-sec time X 10= HR/min
1st QRS - not counted; serves as baseline.
12. 10 Sec time lines:
If HR very slow- longer interval -10 sec taken.
10 Sec = 50 large blocks.
# QRS in 10-sec X 6 = HR/min.
15. First detected: AF detected for 1st time, regardless of
duration or previous episodes.
Recurrent: If >2 episodes ‘ve occurred- may be paroxysmal
or persistent.
Paroxysmal: When recurrent AF has sudden onset & abrupt
termination.
AF that terminates spontaneously or with intervention
within 7 d of onset.
Episodes may recur with variable frequency.
16. Persistent: if AF is >7 days.
Longstanding Persistent AF: continuous AF lasting >1 year.
Not self terminating,
But terminated with pharmacologic/ electrical cardioversion.
Permanent: Permanent AF is used when there has been a joint
decision by the patient and clinician
to cease further attempts to restore and/or maintain sinus rhythm.
· Acceptance of AF represents a therapeutic attitude on the part of
the patient and
clinician rather than an inherent pathophysiological attribute of the
AF.
· Acceptance of AF may change as symptoms, the efficacy of
therapeutic interventions,
and patient and clinician preferences evolve.
17. Nonvalvular AF: in absence of RHD – MV ds, prosthetic
valve, or MV repair.
Valvular AF: - a/w RHD MS, prosthetic valve, or post valve
repair.
Lone AF: AF in age > 60 yrs - with structurally normal hrt,
non HT, no e/o pulmonary dis.
18.
19. AF -mistaken for SVT:
When V. rate is unusually rapid - R-R interval may
look regular because of very close QRS clustering -
thus mistaken for SVT
Diagnosis of AF ascertained by slowing V. rate with
vagal maneuvers eg- CS pr. – showing irreg-irreg R-
R interval with fibrillatory/ undulating baseline b/w
QRS
20. AF mistaken for MAT:
F waves, esp when coarse- mistaken for P waves.
When these “F” waves inscribed before QRS- may be
mistaken for MAT
21. AF with regular R-R intervals:
V. rate in AF is irregularly irregular.
But it becomes regular when there is
complete AV dissociation or
complete AV block.
22. AF with regular R-R intervals:
Complete AV dissociation:
Frequently due to digitalis toxicity.
Here, V. are no longer controlled by AF, but rather
by separate pacemaker, usually AV jnx with regular
rate > 60 bpm.
23. AF with regular R-R intervals:
Complete AV Block :
Fibrillatory impulses not conducted to ventricles.
AV junctional/ ventricular escape rhythm usually
comes to rescue
Here V rate is slow & regular- mid to low 40s
24.
25. Ashman phenomenon:
In AF, R-R intervals are irreg-irreg.
Some R-R are longer & other shorter.
When R-R increased, HR is decreased, RP of
conduction tissues becomes increased.
When R-R decreased or HR increased, RP is
decreased.
26.
27. Ashman phenomenon:
If long R-R is f/b short R-R (long/short cycle), atrial
impulse may find RBB still refractory from previous
impulse & will conduct with wide QRS.
This aberrantly conducted complex is 2nd complex
(complex with short cycle following long cycle).
This variability in RP is k/a Ashman phenomenon
28. Atrial fibrillation & WPW Sx
WPW Sx – Impulses from A to V via AVN + AP.
Unlike AVN, which has >RP; AP has much <RP.
Thus, during AF, rapid A. impulses that are delayed/
blocked at AVN d/t its > RP, are conducted via AP,
resulting in very rapid V rate.
29. Atrial fibrillation & WPW Sx
AVN blocking agents are standard drugs for
controlling V. rate in AF.
H/e These are C/I in WPW sx - they enhance
conduction across AP resulting in rapid V rate &
hemodynamic collapse
32. Atrial Pathology as a Cause of
Atrial Fibrillation
The most frequent patho anatomic changes in AF are
atrial fibrosisand loss of atrial muscle mass.
Patientswith mild or moderate fibrosis responded
more successfully tocardioversion than did those with
severe fibrosis, which was thought to contribute to
persistent AF in cases of valvularheart disease
33. Atrial fibrosis may be caused by genetic defects like
laminAC gene mutations . Other triggers of fibrosis
include inflammationas seen in cardiac sarcoidosis
and autoimmune disorders.
Autoimmune activityis suggested by high serum levels
of antibodies against myosinheavy chains in patients
with paroxysmal AF who have no identified heart
disease
34. Fibrosis is alsotriggered by atrial dilation in any type
of heart disease associatedwith AF, including valvular
disease, hypertension, HF, or coronaryatherosclerosis.
36. Transition of AV reentry into AF in patients with the
Wolff-Parkinson-White(WPW) syndrome can
produce a rapid ventricular response thatdegenerates
into ventricular fibrillation, leading to death .
Intravenous administration of drugs such as
digitalis,verapamil, or diltiazem, which lengthen
refractoriness and slowconduction across the AV
node, does not block conduction overthe accessory
pathway and may accelerate the ventricular rate.
37.
38. A, Focal activation. The initiating focus (indicated by
the star) often lies within the region of the pulmonary
veins. The resulting wavelets represent fibrillatory
conduction, as in multiple-wavelet reentry.
B, Multiple-wavelet reentry. Wavelets (indicated by
arrows) randomly reenter tissue previously activated
by the same or another wavelet.
41. Atrial Fibrillation
-- Prevalence in associated diseases --
Hypertension – increased relative risk of only 1.42; however prevalence
of hypertension accounts for the high association
CAD – AF is transient in 6-10% of MI patients; however it is almost
never in isolation to other ECG findings of ACS (Zimetbaum et al. Incidence and
predictors of myocardial infarction among patients with atrial fibrillation. J Am Coll Cardiol 2000;
36;1223)
Incidence in chronic, stable CHD is 0.6%
Valvular heart disease
High prevalence with Rheumatic heart disease
MS + MR – 52%
MS alone – 29%
MR alone - 16%
AS alone – 1%
Degenerative MR incidence 5% per year
42. Atrial Fibrillation
-- Prevalence in associated diseases, cont. --
Heart Failure – 10-30%
Pulmonary embolism – 10-14 % (rarely the only sign or
symptom)
Hyperthyroidism – low TSH in 5.4%; clinical
hyperthyroidism present in 1%
COPD
Post cardiac surgery
Pericarditis
Obstructive sleep apnea ( for patients with AF and OSA, incidence of AF
recurrence is 2X for those not treated with CPAP)
Congenital heart disease
Peripartum cardiomyopathy
“Holiday Heart”
43. Atrial Fibrillation
-- Pathogenesis --
Underlying heart disease of any cause that is complicated
by:
heart failure
atrial enlargement
elevated atrial pressure
inflammation or infiltration of the atria
Echocardiographic risk factors
increased left ventricular wall thickness
left atrial diameter > 4 cm
reduced left ventricular fractional shortening
Triggering event
majority related to atrial premature beat
minority related to atrial flutter or atrial tachycardia
44.
45.
46.
47. Atrial Fibrillation
-- Management and Disposition --
Which category?
Recent onset AF
Recurrent paroxysmal AF
Recurrent persistent AF
Permanent (Chronic) AF
and patient condition, determines
Which primary option
Rate control
Urgent cardioversion
Delayed cardioversion
Rhythm control / maintenance if converted
Systemic embolization prevention
48. Atrial Fibrillation
-- Management and Disposition --
“Elective” cardioversion in the ED
duration clearly identified less than 48 hrs
No reversible cause
low risk of intra-cardiac thrombus formation
49. Atrial Fibrillation
-- ED Cardioversion in the stable patient --Burton, John H. et al. Electrical cardioversion of ED patients with Atrial
Fibrillation. Annals of Emergency Medicine 2004;44: 22-30
Retrospective, consecutive
cohort
42 months,
Oct 1998 – March 2002
4 institutions
3,688 AF encounters
Excluded: Cardioversion for unstable patients
hypotension, dyspnea, ischemic chest pain, altered
consciousness, CHF, acute MI
No standardized protocol at any of the study sites
388 stable AF encounters
(10.5%)
Mean age = 61 +/- 13 yrs
332 successful (86%)
56 unsuccessful (14%)
91% discharged
55% discharged
9% admitted
45% admitted
50. Atrial Fibrillation
-- Management and Disposition --
“Urgent” or “Emergent” cardioversion in the ED
What are the indications?
What are the contraindications?
51. Atrial Fibrillation
-- Management and Disposition --
Urgent cardioversion
Restoration of sinus rhythm takes precedence over mitigation of thromboembolic risk
Indicated if any of the following is present:
• Active ischemia
• Significant hypotension where LV dysfunction (systolic or diastolic) or valvular
disease is a factor
• Severe CHF
• Pre-excitation syndrome (eg WPW)
“Relative” Contraindications to urgent cardioversion
Duration of episode > 48hrs or uncertain duration
Associated mitral valve disease, cardiomyopathy or CHF (known EF < 50%)
Prior history of thromboembolic event
52.
53.
54. Rate V Rhythm control first?
Rate
Over 65
Coronary artery disease
Unsuitable cardioversion
Unsuitable for
antiarrhythmics
Rhythm
Under 65
Lone AF
CCF
Secondary to treated
trigger
Paroxysmal AF
57. Fast Channel (Na+)
Action Potential
Purkinje fibers
Slow Channel (Ca++)
Action Potential
Sinus / A-V Nodes
0
1
2 3
4
2
0
Myocardial Cellular Electrophysiology
Class 1 antiarrhythmics
-Slowing of conductance
-Phase 0 is determined by Na+ channel
-Slowing of conduction velocity
and decreased excitability
Class 4 antiarrhythmics
-Slowing of AV nodal conductance
-Phase 0 is determined by Ca++ channel
-Slowing of conduction velocity in
sinus and AV nodes
58. -- Antiarrythmic Agent Classification—
Vaughn-Williams Classification
(Journal of Clinical Pharmacology, 1984)
Class 1- depression of Na+conductance during phase 0; slowed conduction
velocity and decreased excitability
1a: moderate depression of Na+ conductance in resting and depolarized tissue;
depression of K+ currents and prolongation of repolarization
Quinidine, Procainamide, Disopyramide
1b: depression of Na+ conductance in depolarized fibers only;
Lidocaine, Tocainide, Phenytoin
1c: marked depression in Na+ conduction; no effect on repolarization
Encainide, Flecainide, Propafenone
Class 2- β-adrenergic receptor blockers
Atenolol, Metoprolol
Class 3- prolongation of action potential duration by varied effects
Bretylium, Sotolol, Amiodarone, Ibutilide, Dofetilide
Class 4- depression of Ca+-dependent slow channels
Diltiazem, Verapamil
59. Atrial Fibrillation
-- Management and Disposition --
Delayed cardioversion
AF duration of 48 hours or duration unknown
Associated mitral valve disease, cardiomyopathy or CHF
Prior history of thromboembolic event
Anticoagulate with a goal INR of 2.0 to 3.0 for at least
three weeks before and four weeks after either electrical
or pharmacologic cardioversion.
60. Atrial Fibrillation
-- Management and Disposition for Delayed ECV --
Strategy 1 (Conventional)
Oral anticoagulation with Warfarin
Target INR 2.0 – 3.0
No antiarrythmics
Rate control as needed – hospitalization usually necessary if rate control needed
Metoprolol
Diltiazem
Digoxin (useful only in presence of CHF)
Scheduled ECV after minimum of 3 weeks of anticoagulation
4 weeks of anticoagulation after ECV
Strategy 2
Indication
recent onset but > 48 hrs
useful for hospitalized patients (rate control, associated complications) and stable patients for
which earlier timing is useful
Patients with increased risk of hemorrhage with anticoagulation
Screening Transesophageal echocardiography (TEE)
No anticoagulation
No antiarrhythmics
Rate control as needed
ECV if no thrombi seen
61. Atrial Fibrillation
-- Indications for hospitalization --
For the treatment of an associated medical
problem, which is often the reason for the
arrhythmia
For elderly patients who are more safely treated for
AF in hospital
For patients with underlying heart disease who
have hemodynamic consequences from the AF or
who are at risk for a complication resulting from
therapy of the arrhythmia
62. Atrial Fibrillation
-- Rate control alone vs rhythm control--
Rhythm control strategy
Advantages:
Better exertional capacity
Improved cardiac function for CHF patients
Mitigation of other arrhythmic related symptoms (eg palpitations)
Disadvantages:
frequent recurrences of AF – 50% of patient recurr in 3-6 months
repeated need for electrical cardioversion;
adverse effects of prophylactic antiarrhythmic drugs including life-threatening
events related to proarrhythmic effects
No clear benefit of either approach for patients over 65 years of age;
trend for increased mortality in rhythm control (AFFIRM trial, NEJM 2002,
> 4,000 patients)
Rate control with anticoagulation is acceptable in patients 65 yrs or
greater
Strategy is weighed for acutely symptomatic patient with new onset of
Atrial fibrillation, particularly if < 65 yrs
63. Atrial Fibrillation
-- Rate control alone vs rhythm control --
VanGelder, et al, A Comparison of Rate Control and Rhythm Control in
Patients with Recurrent Persistent Atrial Fibrillation, NEJM
2002;347:1834-40
522 Patients with persistent AF after
previous electrical cardioversion
Mean age 68 +/- 8
Mean duration of AF diagnosis 315 d
Mean duration of presenting episode 32 d
No history of heart disease 21%
Primary Endpoints:
Death
CHF
TE event
Bleeding
Pacer
severe drug adverse event
Primary endpoint:
Rhythm control = 23%
Rate control = 17%
Follow up period of at least 2 yrs
Rhythm control Rate control
Entry: ECV + Sotolol
1st recurrence: ECV +
Flecanide or Propafenone
2nd recurrence: Amiodarone load +
ECV + Amiodarone main.
Target HR < 100
Digoxin, Diltiazem,
β blocker – alone or
In combination
All patients anticoagulated: could be discontinued if
In NSR 4 weeks after ECV
64. Atrial Fibrillation
-- Rate control alone vs rhythm control --
VanGelder, et al, A Comparison of Rate Control and Rhythm
Control in Patients with Recurrent Persistent Atrial
Fibrillation, NEJM 2002;347:1834-40
Factors related to lack of risk reduction with rhythm control strategy
•Tachycardia induced cardiomyopathy and heart failure also are
likely reduced with rate control (incidence of CHF similar in
the two arms of the study)
•Patients with risk factors for stroke are still at risk for stroke even
when sinus rhythm is maintained (17% of the thromboembolic
events occurred after cessation of anticoagulant therapy and in
5 of 6 cases the patient was in sinus rhythm at the time of the event)
•Senescent conduction disease is occasionally unmasked by rhythm
control strategy
65. Atrial Fibrillation
-- Maintenance of Sinus Rhythm after Chemical or Electrical Cardioversion --
Canadian Trial of Atrial Fibrillation Investigators
Roy, et al Amiodarone to Prevent Recurrence of Atrial Fibrillation, NEJM,
2000;342:913-920403 patients; 19 centers
201 Amiodarone 202 Propafenone ; Sotolol
101 Propafenone 101 Sotolol
Mean 16 month follow-up
35% recurrence for Amiodarone 63% recurrence for Propafenone or Sotolol
66. Atrial Fibrillation
-General Management Principles-
-- Pharmacologic Cardioversion -- Semi – urgent (hospitalization or Obs Unit)
Class 1c
used only if no pre-existant heart disease
monitoring for rapid conducting At. Flutter
Flecainide
Propafenone
Class 3
monitoring for QT prolongation; Torsade
Dofetilide
Ibutilide
Out-patient / Ambulatory scenario
Class 1c “Pill-in-the-Pocket”
Flecainide
Propafenone
Used only when demonstrated effective under as in-patient
Must have AV nodal blockade with β blockade or Ca++ channel blocker to prevent 1:1
AV conduction if Atrial flutter occurs
Class 1c Extended dosing
Amiodarone –particularly with patients with pre-existing heart disease
67. Atrial Fibrillation
-General Management Principles-
-- Maintenance of Sinus Rhythm after Chemical or Electrical Cardioversion –
ACC / AHA / ESC anticoagulation recommendations
71. Atrial Fibrillation
-- Prevention of Thromboembolism --
ACC / AHA / ESC anticoagulation recommendations
Age < 60 + heart disease but no other risks: Aspirin
Age 60 – 75 with no risks: Aspirin
Age 65 – 75 with heart disease or DM: Warfarin
Women > 75: Warfarin
Men > 75: Warfarin or Aspirin
Age > 65 with CHF: Warfarin
EF < 35% + Hypertension Warfarin
72. CHA2DS2-VASc acronym
Congestive HF
Hypertension
Age ≥75 y
Diabetes mellitus
Stroke/TIA/TE
Vascular disease (prior MI,
PAD, or aortic plaque)
Age 65–74 y
Sex category (i.e., female sex
Maximum Score
1
1
2
1
2
1
1
1
9
75. Atrial Fibrillation
-- Summary –
Patients with new onset atrial fibrillation of less than 48 hrs duration, who
have normal ventricular function, no known mitral valvular disease and no
history of thromboembolic event can be considered for cardioversion in the
ED
Up to 90% of atrial fibrillation episodes are asymptomatic with
approximately 20% of such episodes longer than 48 hrs (Select your
cardioversion cases carefully!)
If the episode is greater than 48hrs, rate control, anticoagulate and refer for
delayed cardioversion
TSH and free T4 are essential in the evaluation of initial onset
AF is transient in 6-10% of MI patients; however it is almost never in
isolation to other ECG findings of ACS
AF is transient in 6-10% of MI patients; however it is almost never in
isolation to other ECG findings of ACS
76. The following are 10 points to remember about the 2014 guideline for the
management of patients with nonvalvular atrial fibrillation (AF):
1. In assessing risk of stroke in a patient with nonvalvular AF, the writing
committee recommends (Class I) the usage of the CHA2DS2-VASc (C=congestive
heart failure; H=hypertension; A2=age ≥75 years [doubled]; D=diabetes mellitus;
S2=stroke, transient ischemic attack, or thromboembolism [doubled];
V=vascular disease; A=age 65-74 years; Sc=sex category, i.e., female gender)
score, as opposed to the CHADS2 score.
2. For nonvalvular AF patients with a history of stroke or transient ischemic
attack, or a CHA2DS2-VASc score ≥2, oral anticoagulation is recommended
(Class I). Options for oral anticoagulation include warfarin, dabigatran,
rivaroxaban, and apixaban.
3. For patients with nonvalvular AF and a CHA2DS2-VASc score of 0, it is
reasonable to omit antithrombotic therapy (Class IIa).
4. The following options may be considered with a patient with nonvalvular AF
and a CHA2DS2-VASc score of 1: no antithrombotic therapy, oral
anticoagulation, or aspirin (Class IIb).
77. 5. None of the novel oral anticoagulants (dabigatran, rivaroxaban, or apixaban) are
recommended to be used in patients with AF and a mechanical or bioprosthetic heart
valve (Class III harm).
6. As in the earlier guidelines, the committee recommends against the use of certain
antiarrhythmic medications (flecainide, propafenone, dofetilide, and sotalol) in patients
with severe left ventricular hypertrophy (LVH). In the current guidelines, severe LVH is
now defined as wall thickness exceeding 1.5 cm.
7. Oral anticoagulation should be prescribed to patients with hypertrophic
cardiomyopathy and AF irrespective of the CHA2DS2-VASc score (Class I).
8. A randomized trial suggested that a lenient (<110 bpm) rate control strategy was as
effective as a strict strategy (<80 bpm) in patients with persistent/permanent AF.
However, the writing committee still advocates for the latter (Class IIa), as the results of
this single trial were not thought to be definitive.
9. Catheter ablation is useful in patients with symptomatic, paroxysmal AF who have not
responded to or tolerated antiarrhythmic medications (Class I).
10. Catheter ablation is also reasonable in selected patients with symptomatic, paroxysmal
AF prior to a trial of medical therapy, provided that it can be performed at an experienced
center (Class IIa).